0	15	Transcriptional	transcriptional	JJ
16	24	activity	activity	NN
25	27	of	of	IN
28	32	core	core	NN
33	40	binding	binding	NN
41	53	factor-alpha	factor-alpha	NN
54	55	(	(	(
55	59	AML1	AML1	NNP
59	60	)	)	)
61	64	and	and	CC
65	69	beta	beta	NN
70	78	subunits	subunit	NNS
79	81	on	on	IN
82	88	murine	murine	JJ
89	97	leukemia	leukemia	NN
98	103	virus	virus	NN
104	112	enhancer	enhancer	NN
113	118	cores	core	NNS
118	119	.	.	.

121	125	Core	Core	NNP
126	133	binding	binding	NN
134	140	factor	factor	NN
141	142	(	(	(
142	145	CBF	CBF	NNP
145	146	)	)	)
146	147	,	,	,
148	152	also	also	RB
153	158	known	know	VBN
159	161	as	as	IN
162	174	polyomavirus	polyomavirus	NN
175	191	enhancer-binding	enhancer-binding	JJ
192	199	protein	protein	NN
200	201	2	2	CD
202	205	and	and	CC
206	209	SL3	sl3	NN
210	218	enhancer	enhancer	NN
219	225	factor	factor	NN
226	227	1	1	CD
227	228	,	,	,
229	231	is	be	VBZ
232	233	a	a	DT
234	243	mammalian	mammalian	JJ
244	257	transcription	transcription	NN
258	264	factor	factor	NN
265	269	that	that	WDT
270	275	binds	bind	VBZ
276	278	to	to	TO
279	281	an	an	DT
282	289	element	element	NN
290	296	termed	term	VBN
297	300	the	the	DT
301	305	core	core	NN
306	312	within	within	IN
313	316	the	the	DT
317	326	enhancers	enhancer	NNS
327	329	of	of	IN
330	333	the	the	DT
334	340	murine	murine	JJ
341	349	leukemia	leukemia	NN
350	355	virus	virus	NN
356	362	family	family	NN
363	365	of	of	IN
366	378	retroviruses	retrovirus	NNS
378	379	.	.	.

380	383	The	the	DT
384	388	core	core	NN
389	397	elements	element	NNS
398	400	of	of	IN
401	404	the	the	DT
405	408	SL3	sl3	NN
409	414	virus	virus	NN
415	418	are	be	VBP
419	428	important	important	JJ
429	436	genetic	genetic	JJ
437	449	determinants	determinant	NNS
450	452	of	of	IN
453	456	the	the	DT
457	464	ability	ability	NN
465	467	of	of	IN
468	472	this	this	DT
473	478	virus	virus	NN
479	481	to	to	TO
482	488	induce	induce	VB
489	495	T-cell	t-cell	NN
496	505	lymphomas	lymphoma	NNS
506	509	and	and	CC
510	513	the	the	DT
514	529	transcriptional	transcriptional	JJ
530	538	activity	activity	NN
539	541	of	of	IN
542	545	the	the	DT
546	551	viral	viral	JJ
552	556	long	long	JJ
557	565	terminal	terminal	JJ
566	572	repeat	repeat	NN
573	575	in	in	IN
576	577	T	t	NN
578	589	lymphocytes	lymphocyte	NNS
589	590	.	.	.

591	594	CBF	CBF	NNP
595	603	consists	consist	VBZ
604	606	of	of	IN
607	610	two	two	CD
611	619	subunits	subunit	NNS
619	620	,	,	,
621	622	a	a	DT
623	626	DNA	DNA	NNP
627	634	binding	binding	NN
635	642	subunit	subunit	NN
642	643	,	,	,
644	647	CBF	CBF	NNP
648	653	alpha	alpha	NN
653	654	,	,	,
655	658	and	and	CC
659	660	a	a	DT
661	667	second	second	JJ
668	675	subunit	subunit	NN
675	676	,	,	,
677	680	CBF	CBF	NNP
681	685	beta	beta	NN
685	686	,	,	,
687	691	that	that	WDT
692	702	stimulates	stimulate	VBZ
703	706	the	the	DT
707	710	DNA	dna	NN
711	718	binding	binding	NN
719	727	activity	activity	NN
728	730	of	of	IN
731	734	CBF	CBF	NNP
735	740	alpha	alpha	NN
740	741	.	.	.

742	745	One	one	CD
746	748	of	of	IN
749	752	the	the	DT
753	758	genes	gene	NNS
759	763	that	that	WDT
764	771	encodes	encode	VBZ
772	773	a	a	DT
774	777	CBF	CBF	NNP
778	783	alpha	alpha	NN
784	791	subunit	subunit	NN
792	794	is	be	VBZ
795	799	AML1	aml1	NN
799	800	,	,	,
801	805	also	also	RB
806	812	called	call	VBN
813	816	Cbf	Cbf	NNP
817	822	alpha	alpha	NN
823	824	2	2	CD
824	825	.	.	.

826	830	This	this	DT
831	836	locus	locus	NN
837	839	is	be	VBZ
840	850	rearranged	rearrange	VBN
851	853	by	by	IN
854	865	chromosomal	chromosomal	JJ
866	880	translocations	translocation	NNS
881	883	in	in	IN
884	889	human	human	JJ
890	908	myeloproliferative	myeloproliferative	JJ
909	918	disorders	disorder	NNS
919	922	and	and	CC
923	932	leukemias	leukemia	NNS
932	933	.	.	.

934	936	An	an	DT
937	948	exogenously	exogenously	RB
949	958	expressed	express	VBN
959	962	Cbf	Cbf	NNP
963	968	alpha	alpha	NN
969	978	2-encoded	2-encoded	JJ
979	986	subunit	subunit	NN
987	988	(	(	(
988	991	CBF	CBF	NNP
992	997	alpha	alpha	NN
998	1003	2-451	2-451	CD
1003	1004	)	)	)
1005	1015	stimulated	stimulate	VBD
1016	1029	transcription	transcription	NN
1030	1034	from	from	IN
1035	1038	the	the	DT
1039	1042	SL3	sl3	NN
1043	1051	enhancer	enhancer	NN
1052	1054	in	in	IN
1055	1058	P19	P19	NNP
1059	1062	and	and	CC
1063	1067	HeLa	HeLa	NNP
1068	1073	cells	cell	NNS
1073	1074	.	.	.

1075	1083	Activity	activity	NN
1084	1087	was	be	VBD
1088	1096	mediated	mediate	VBN
1097	1104	through	through	IN
1105	1108	the	the	DT
1109	1113	core	core	NN
1114	1122	elements	element	NNS
1122	1123	.	.	.

1124	1129	Three	three	CD
1130	1139	different	different	JJ
1140	1148	isoforms	isoform	NNS
1149	1151	of	of	IN
1152	1155	CBF	CBF	NNP
1156	1160	beta	beta	NN
1161	1165	were	be	VBD
1166	1170	also	also	RB
1171	1177	tested	test	VBN
1178	1181	for	for	IN
1182	1197	transcriptional	transcriptional	JJ
1198	1206	activity	activity	NN
1207	1209	on	on	IN
1210	1213	the	the	DT
1214	1217	SL3	sl3	NN
1218	1226	enhancer	enhancer	NN
1226	1227	.	.	.

1228	1231	The	the	DT
1232	1239	longest	long	JJS
1240	1244	form	form	NN
1244	1245	,	,	,
1246	1249	CBF	CBF	NNP
1250	1258	beta-187	beta-187	NN
1258	1259	,	,	,
1260	1269	increased	increase	VBD
1270	1273	the	the	DT
1274	1289	transcriptional	transcriptional	JJ
1290	1301	stimulation	stimulation	NN
1302	1304	by	by	IN
1305	1308	CBF	CBF	NNP
1309	1314	alpha	alpha	NN
1315	1320	2-451	2-451	CD
1321	1328	twofold	twofold	RB
1329	1331	in	in	IN
1332	1336	HeLa	HeLa	NNP
1337	1342	cells	cell	NNS
1342	1343	,	,	,
1344	1352	although	although	IN
1353	1355	it	it	PRP
1356	1359	had	have	VBD
1360	1362	no	no	DT
1363	1369	effect	effect	NN
1370	1372	in	in	IN
1373	1376	P19	p19	NN
1377	1382	cells	cell	NNS
1382	1383	.	.	.

1384	1399	Transcriptional	transcriptional	JJ
1400	1410	activation	activation	NN
1411	1413	by	by	IN
1414	1417	CBF	CBF	NNP
1418	1422	beta	beta	NN
1423	1431	required	require	VBD
1432	1439	binding	binding	NN
1440	1442	to	to	TO
1443	1446	the	the	DT
1447	1450	CBF	CBF	NNP
1451	1456	alpha	alpha	NN
1457	1464	subunit	subunit	NN
1464	1465	,	,	,
1466	1468	as	as	IN
1469	1470	a	a	DT
1471	1475	form	form	NN
1476	1478	of	of	IN
1479	1482	CBF	CBF	NNP
1483	1487	beta	beta	NN
1488	1492	that	that	WDT
1493	1499	lacked	lack	VBD
1500	1507	binding	binding	NN
1508	1515	ability	ability	NN
1515	1516	,	,	,
1517	1520	CBF	CBF	NNP
1521	1529	beta-148	beta-148	NN
1529	1530	,	,	,
1531	1537	failed	fail	VBD
1538	1540	to	to	TO
1541	1549	increase	increase	VB
1550	1558	activity	activity	NN
1558	1559	.	.	.

1560	1565	These	these	DT
1566	1573	results	result	NNS
1574	1583	indicated	indicate	VBD
1584	1588	that	that	IN
1589	1591	at	at	IN
1592	1597	least	least	JJS
1598	1600	in	in	IN
1601	1608	certain	certain	JJ
1609	1613	cell	cell	NN
1614	1619	types	type	NNS
1619	1620	,	,	,
1621	1624	the	the	DT
1625	1632	maximum	maximum	NN
1633	1641	activity	activity	NN
1642	1644	of	of	IN
1645	1648	CBF	CBF	NNP
1649	1657	required	require	VBD
1658	1662	both	both	DT
1663	1671	subunits	subunit	NNS
1671	1672	.	.	.

1673	1677	They	they	PRP
1678	1682	also	also	RB
1683	1691	provided	provide	VBD
1692	1699	support	support	NN
1700	1703	for	for	IN
1704	1707	the	the	DT
1708	1718	hypothesis	hypothesis	NN
1719	1723	that	that	IN
1724	1727	CBF	CBF	NNP
1728	1730	is	be	VBZ
1731	1732	a	a	DT
1733	1739	factor	factor	NN
1740	1742	in	in	IN
1743	1744	T	t	NN
1745	1756	lymphocytes	lymphocyte	NNS
1757	1761	that	that	WDT
1762	1764	is	be	VBZ
1765	1776	responsible	responsible	JJ
1777	1780	for	for	IN
1781	1792	recognition	recognition	NN
1793	1795	of	of	IN
1796	1799	the	the	DT
1800	1803	SL3	sl3	NN
1804	1809	cores	core	NNS
1809	1810	.	.	.

1811	1813	We	we	PRP
1814	1818	also	also	RB
1819	1827	examined	examine	VBD
1828	1835	whether	whether	IN
1836	1839	CBF	CBF	NNP
1840	1845	could	could	MD
1846	1857	distinguish	distinguish	VB
1858	1859	a	a	DT
1860	1864	1-bp	1-bp	JJ
1865	1875	difference	difference	NN
1876	1883	between	between	IN
1884	1887	the	the	DT
1888	1896	enhancer	enhancer	NN
1897	1901	core	core	NN
1902	1904	of	of	IN
1905	1908	SL3	SL3	NNP
1909	1912	and	and	CC
1913	1916	the	the	DT
1917	1921	core	core	NN
1922	1924	of	of	IN
1925	1928	the	the	DT
1929	1944	nonleukemogenic	nonleukemogenic	JJ
1945	1950	virus	virus	NN
1950	1951	,	,	,
1952	1955	Akv	Akv	NNP
1955	1956	.	.	.

1957	1961	This	this	DT
1962	1972	difference	difference	NN
1973	1981	strongly	strongly	RB
1982	1989	affects	affect	VBZ
1990	2003	transcription	transcription	NN
2004	2006	in	in	IN
2007	2008	T	t	NN
2009	2014	cells	cell	NNS
2015	2018	and	and	CC
2019	2034	leukemogenicity	leukemogenicity	NN
2035	2037	of	of	IN
2038	2041	SL3	SL3	NNP
2041	2042	.	.	.

2043	2050	However	however	RB
2050	2051	,	,	,
2052	2054	no	no	DT
2055	2066	combination	combination	NN
2067	2069	of	of	IN
2070	2073	CBF	CBF	NNP
2074	2079	alpha	alpha	NN
2080	2083	and	and	CC
2084	2087	CBF	cbf	NN
2088	2092	beta	beta	NN
2093	2101	subunits	subunit	NNS
2102	2106	that	that	WDT
2107	2109	we	we	PRP
2110	2116	tested	test	VBD
2117	2120	was	be	VBD
2121	2125	able	able	JJ
2126	2128	to	to	TO
2129	2140	distinguish	distinguish	VB
2141	2144	the	the	DT
2145	2149	1-bp	1-bp	JJ
2150	2160	difference	difference	NN
2161	2163	in	in	IN
2164	2177	transcription	transcription	NN
2178	2184	assays	assay	NNS
2184	2185	.	.	.

2186	2190	Thus	thus	RB
2190	2191	,	,	,
2192	2193	a	a	DT
2194	2202	complete	complete	JJ
2203	2216	understanding	understanding	NN
2217	2219	of	of	IN
2220	2223	how	how	WRB
2224	2225	T	t	NN
2226	2231	cells	cell	NNS
2232	2241	recognize	recognize	VBP
2242	2245	the	the	DT
2246	2249	SL3	sl3	NN
2250	2254	core	core	NN
2255	2262	remains	remain	VBZ
2263	2265	to	to	TO
2266	2268	be	be	VB
2269	2279	elucidated	elucidate	VBN
2279	2280	.	.	.